Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To evaluate the safety and tolerability of long-term therapy with 1 dose level of oral CCI-779 (temsirolimus; 8 mg/day) administered to subjects with relapsing-remitting or secondary progressive MS with relapses who completed study 3066A2-210-WW.
Critère d'inclusion
- Multiple Sclerosis (Relapsing-remitting MS and Secondary progressive MS with relapses)